Get healthy returns from these three innovative healthcare stocks
Professional investor Michael Li of the American Century Advanced Medical Impact Fund looks at three healthcare stocks
Healthcare is an exciting sector. The incredibly rapid development of effective coronavirus vaccines is just one example of its tremendous potential for innovation and making a positive social impact. We also feel there is scope for healthy returns. Healthcare companies are innovating not just in therapeutics and medical devices, but also in terms of big data and analytics. As a result, we believe we are on the verge of a transformation in how care is delivered and diseases are treated.
Speeding up drug trials
Veeva Systems (NYSE: VEEV) is a cloud-software company whose technology helps plan drug trials safely and effectively. The process of developing a new drug takes over a decade and costs millions of dollars. This use of data analytics and information technology helps reduce approval times and costs, and raises the probability of success.
The company serves over 750 customers, including 20 of the largest pharmaceutical companies. Its technology typically accelerates regulatory submissions by 20%, which is crucial for patients likely to benefit from innovative treatments. Veeva’s platform also accelerates drug development by reducing the start-up time in clinical studies by 40%.
Subscribe to MoneyWeek
Subscribe to MoneyWeek today and get your first six magazine issues absolutely FREE
Sign up to Money Morning
Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter
Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter
A cocktail to combat Covid-19
Regeneron Pharmaceuticals (Nasdaq: REGN) is a biotechnology company engaged in the development of medicines for the treatment of serious diseases. It is pouring resources into research and development (R&D) and it maintains one of the world’s most comprehensive genetic databases, with a million people sequenced by the Regeneron Genetics Center. Regeneron is well known today for its Covid-19 antiviral drug cocktail, which has so far proved effective against the various strains of the disease, and is gaining market share from competing therapies. But Regeneron’s research effort goes far beyond Covid-19.
The company has developed and markets drugs addressing several serious medical conditions, including a type of inoperable skin cancer, wet age-related macular degeneration, asthma and eczema among others. Regeneron has approximately 30 potential treatments in clinical development.
Transforming diabetes care
DexCom (Nasdaq: DXCM) is an innovative medical-device company transforming the quality of life and standard of care for diabetics. The company produces a continuous glucose monitoring (CGM) system, which allows patients and care providers to evaluate and adjust care quickly and effectively in real time.
A sensor is placed under the patient’s skin and attached to a tiny transmitter that continuously relays data on blood-sugar levels. The data can be read on a dedicated receiver, displayed on an iPhone, or monitored remotely by a care provider. This technology is transformative: traditional glucose monitoring depends on intermittent, inconvenient and painful finger pricks and self-monitoring.
Not only is DexCom attractive for its positive impact on the lives of diabetics, but the company is also gaining market share, broadening the range of potential applications for its products and expanding geographically.
Sign up to Money Morning
Our team, led by award winning editors, is dedicated to delivering you the top news, analysis, and guides to help you manage your money, grow your investments and build wealth.
-
Twenty 'finfluencers' questioned under caution by the UK regulator
The individuals were interviewed voluntarily using the Financial Conduct Authority’s criminal powers
By Chris Newlands Published
-
Number of ISA millionaires triples in three years
The number of people with £1 million in their ISAs has tripled in three years to reach 3,180. But could next week’s Budget put an end to future ISA millionaires?
By Ruth Emery Published
-
Should you invest in Canada?
Canada presents a compelling opportunity for investors who want to look beyond the US. Greg Eckel of Canadian General Investments highlights four favourites
By Greg Eckel Published
-
What will a broken-up Google look like?
The US courts have ruled that Google is a monopoly, leaving it facing the prospect of a break-up. WIll that be a good thing?
By Matthew Lynn Published
-
How will the UK gambling sector be hit by the Budget?
There are concerns for the UK gambling sector in the lead-up to the Autumn Budget. What could be on the cards?
By Dr Matthew Partridge Published
-
HSBC returns to cost-cutting plan
HSBC is set to revamp its commercial banking division – but will it come at a cost?
By Dr Matthew Partridge Published
-
Will European stocks bounce back?
European stocks have looked unattractive for some time – will they bounce back?
By Alex Rankine Published
-
British American Tobacco goes smokeless – can it survive?
British American Tobacco’s core product is struggling, but new areas bode well, says Bruce Packard
By Bruce Packard Published
-
Pfizer shares rise as US investor takes $1 billion stake
Pfizer shares are on the up since US activist investor Starboard Value built up a stake in the drug maker. But strategic options appear limited
By Dr Matthew Partridge Published
-
LSL Property Services: a profit-machine in the property sector
LSL covers every area of the residential real estate market and should thrive after its shake-up
By Rupert Hargreaves Published